These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36860911)

  • 21. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.
    Singh H; Figliola MJ; Dawson MJ; Huls H; Olivares S; Switzer K; Mi T; Maiti S; Kebriaei P; Lee DA; Champlin RE; Cooper LJ
    Cancer Res; 2011 May; 71(10):3516-27. PubMed ID: 21558388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.
    Nakazawa Y; Matsuda K; Kurata T; Sueki A; Tanaka M; Sakashita K; Imai C; Wilson MH; Koike K
    J Hematol Oncol; 2016 Mar; 9():27. PubMed ID: 26983639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9.
    Liu L; Bi E; Ma X; Xiong W; Qian J; Ye L; Su P; Wang Q; Xiao L; Yang M; Lu Y; Yi Q
    Nat Commun; 2020 Nov; 11(1):5902. PubMed ID: 33214555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome.
    Arcangeli S; Bove C; Mezzanotte C; Camisa B; Falcone L; Manfredi F; Bezzecchi E; El Khoury R; Norata R; Sanvito F; Ponzoni M; Greco B; Moresco MA; Carrabba MG; Ciceri F; Bonini C; Bondanza A; Casucci M
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35503659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted Rejuvenation of Exhausted Chimeric Antigen Receptor T Cells Regresses Refractory Solid Tumors.
    Luo Q; Napoleon JV; Liu X; Zhang B; Zheng S; Low PS
    Mol Cancer Res; 2022 May; 20(5):823-833. PubMed ID: 35135862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia.
    Zebley CC; Brown C; Mi T; Fan Y; Alli S; Boi S; Galletti G; Lugli E; Langfitt D; Metais JY; Lockey T; Meagher M; Triplett B; Talleur AC; Gottschalk S; Youngblood B
    Cell Rep; 2021 Nov; 37(9):110079. PubMed ID: 34852226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
    Gargett T; Brown MP
    Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma.
    Aspuria PJ; Vivona S; Bauer M; Semana M; Ratti N; McCauley S; Riener R; de Waal Malefyt R; Rokkam D; Emmerich J; Kastelein RA; Lupardus PJ; Oft M
    Sci Transl Med; 2021 Dec; 13(625):eabg7565. PubMed ID: 34936383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion.
    Kaartinen T; Luostarinen A; Maliniemi P; Keto J; Arvas M; Belt H; Koponen J; Mäkinen PI; Loskog A; Mustjoki S; Porkka K; Ylä-Herttuala S; Korhonen M
    Cytotherapy; 2017 Jun; 19(6):689-702. PubMed ID: 28411126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.
    Hurton LV; Singh H; Najjar AM; Switzer KC; Mi T; Maiti S; Olivares S; Rabinovich B; Huls H; Forget MA; Datar V; Kebriaei P; Lee DA; Champlin RE; Cooper LJ
    Proc Natl Acad Sci U S A; 2016 Nov; 113(48):E7788-E7797. PubMed ID: 27849617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models.
    Mu-Mosley H; Ostermann L; Muftuoglu M; Vaidya A; Bonifant CL; Velasquez MP; Gottschalk S; Andreeff M
    Front Immunol; 2022; 13():880108. PubMed ID: 35615350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stem cell like memory T cells: A new paradigm in cancer immunotherapy.
    Wang F; Cheng F; Zheng F
    Clin Immunol; 2022 Aug; 241():109078. PubMed ID: 35840054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
    Front Immunol; 2020; 11():580328. PubMed ID: 33384686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigen-specific CD8+ memory stem T cells generated from human peripheral blood effectively eradicate allogeneic targets in mice.
    Guan L; Li X; Wei J; Liang Z; Yang J; Weng X; Wu X
    Stem Cell Res Ther; 2018 Dec; 9(1):337. PubMed ID: 30526661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies.
    Beider K; Itzhaki O; Schachter J; Grushchenko-Polaq AH; Voevoda-Dimenshtein V; Rosenberg E; Ostrovsky O; Devillers O; Shapira Frommer R; Zeltzer LA; Toren A; Jacoby E; Shimoni A; Avigdor A; Nagler A; Besser MJ
    Cells; 2022 Mar; 11(7):. PubMed ID: 35406703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Saito S; Nakazawa Y; Sueki A; Matsuda K; Tanaka M; Yanagisawa R; Maeda Y; Sato Y; Okabe S; Inukai T; Sugita K; Wilson MH; Rooney CM; Koike K
    Cytotherapy; 2014 Sep; 16(9):1257-69. PubMed ID: 25108652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antioxidant metabolism regulates CD8+ T memory stem cell formation and antitumor immunity.
    Pilipow K; Scamardella E; Puccio S; Gautam S; De Paoli F; Mazza EM; De Simone G; Polletti S; Buccilli M; Zanon V; Di Lucia P; Iannacone M; Gattinoni L; Lugli E
    JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy.
    Kawai Y; Kawana-Tachikawa A; Kitayama S; Ueda T; Miki S; Watanabe A; Kaneko S
    Mol Ther; 2021 Oct; 29(10):3027-3041. PubMed ID: 34023508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.